xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.
xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.
xofigo
bayer ag - radium (223ra) dichloride - prostatic neoplasms - therapeutic radiopharmaceuticals - xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
xofigo solution
bayer inc - radium ra-223 dichloride - solution - 1100kbq - radium ra-223 dichloride 1100kbq - radioactive agents
xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.
xofigo
bayer israel ltd - radium-223 dichloride - solution for injection - radium-223 dichloride 1100 kbq/ml at reference date - radium (223 ra) dichloride - xofigo monotherapy or in combination with luteinising hormone releasing hormone (lhrh) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc), symptomatic bone metastases and no known visceral metastases, in progression after at least two prior lines of systemic therapy for advanced pc (other than lhrh analogues), or ineligible for any available systemic mcrpc treatment.
xofigo solution for injection 1100kbqml
bayer (south east asia) pte ltd - radium-223 chloride - injection, solution (radiopharmaceutical) - 1000 kbq/ml - radium-223 chloride 1100 kbq/ml
xofigo injection
bayer (pty) ltd û isando - injection - see ingredients - each 1,0 ml solution contains radium-224 0,53 ng